{"entity":{"id":"adaptin-bio","kind":"company","name":"Adaptin Bio","aka":["Adaptin Bio, Inc."],"tldr":"Adaptin Bio is a North Carolina company working on ways to get immune treatments past the barrier that protects the brain. Its first medicine, APTN-101, is in an early trial at Duke University in glioblastoma.","summary":"Adaptin Bio, Inc., of Charlotte, North Carolina, develops technology originally from the Department of Neurosurgery at Duke University, led by John H. Sampson, that uses activated T cells to carry bound molecules across the blood-brain barrier. Its first platform, BRiTE (Brain Bispecific T-cell Engager), pairs this with a tumour-specific, fully human bispecific antibody. The first product, APTN-101, is an EGFRvIII x CD3 BRiTE. The FDA accepted an investigator-initiated IND in May 2023 and a multi-dose amendment in October 2025, and in August 2026 Duke opened an investigator-initiated phase 1 trial of hEGFRvIII-CD3 bi-scFv in WHO grade 4 malignant glioma.","asOf":"2026-11-04","links":[{"label":"SEC: Adaptin Bio Form S-1, August 2026","url":"https://www.sec.gov/Archives/edgar/data/1938571/000121390026095034/ea0303043-s1_adaptin.htm"},{"label":"Official website","url":"https://www.adaptinbio.com/"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["t-cell-engager","bispecific-antibody"],"targets":["cd3"],"drugs":["aptn-101"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on 4 November 2026 in the S-1 filed with the SEC on 28 August 2026. The trial registry number is not given in the filing."],"hq":"Charlotte, NC","country":"US","companyType":"biotech","website":"https://www.adaptinbio.com/","ticker":"APTN","stage":"public","investors":[],"funding":[]},"route":"/companies/adaptin-bio/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"drug":[{"id":"aptn-101","kind":"drug","name":"APTN-101","route":"/drugs/aptn-101/"}]}}